Exploring 4 Patient-Centric Trends Shaping Today's Biopharma Landscape

Patient centricity has been a talking point in pharma for years, but something has shifted. The industry is now actually restructuring how drugs are developed and made around it, and the operational changes are more substantial than the rhetoric usually suggests.

Four trends are driving this transformation. Post-COVID supply chain redesign tops the list: the pandemic exposed just how fragile globally distributed active pharmaceutical ingredient (API) sourcing can be, and sponsors have spent the past four years building in redundancy and geographic diversification. Decentralized clinical trials (DCTs) are reducing the burden on patients who previously had to travel to study sites. Patient-friendly formulations, such as modified-release dosage forms and alternative delivery routes, are being prioritized earlier in development rather than treated as afterthoughts. And strategic partnerships between contract research organizations (CROs) and contract development and manufacturing organizations (CDMOs) are enabling more integrated, patient-informed drug development pathways.

If you work in pharma development or manufacturing strategy, these aren't distant trends. They're already influencing how programs are structured and resourced. Access the full analysis to see where your planning should be adapting.